scholarly journals Comparison of Long-Term Oncological Outcomes in Oncoplastic Breast Surgery and Conventional Breast-Conserving Surgery for Breast Cancer: A Propensity Score-Matched Analysis

2021 ◽  
Vol 24 ◽  
Author(s):  
Moon Young Oh ◽  
Yumi Kim ◽  
Jiho Kim ◽  
Jong-Ho Cheun ◽  
Ji Gwang Jung ◽  
...  
2018 ◽  
pp. 294-299
Author(s):  
Lashan Peiris ◽  
David Olson ◽  
Kelly Dabbs

Oncoplastic breast surgery combines certain plastic surgery procedures with a breast cancer resection to minimize the cosmetic penalty. We compared current practices in breast surgery in Canada and the UK, looking at the classification of oncoplastic breast surgery, management of larger tumours that would otherwise mandate a mastectomy, and the breast surgeon’s role in immediate breast reconstruction. Reconstructive breast surgery has always fallen within the domain of the plastic surgeon, but surgical subspecialization and more focused fellowship training have meant that breast surgeons with the appropriate skillset can offer these procedures. This evolution of the breast surgeon has led to the birth of a new field of breast surgery known as oncoplastic and reconstructive breast surgery. Those tasked with developing surgical training programs in Canada must now decide whether to train breast surgeons in these techniques to improve long-term quality of life among Canadian patients with breast cancer.


2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Wolfram Malter ◽  
Verena Kirn ◽  
Lisa Richters ◽  
Claudius Fridrich ◽  
Birgid Markiefka ◽  
...  

Breast-conserving surgery followed by whole-breast irradiation is the standard local therapy for early breast cancer. The international discussion of reduced importance of wider tumor-free resection margins than “tumor not touching ink” leads to the development of five principles in targeted oncoplastic breast surgery. IORT improves local recurrence risk and diminishes toxicity since there is less irradiation of healthy tissue. Intraoperative radiotherapy (IORT) can be delivered in two settings: an IORT boost followed by a conventional regimen of external beam radiotherapy or a single IORT dose. The data from TARGIT-A and ELIOT reinforce the conviction that intraoperative radiotherapy during breast-conserving surgery is a reliable alternative to conventional postoperative fractionated irradiation, but only in a carefully selected population at low risk of local recurrence. We describe our experiences with IORT boost (50 kV energy X-rays; 20 Gy) in combination with targeted oncoplastic breast surgery in a routine clinical setting. Our experiences demonstrate the applicability and reliability of combining IORT boost with targeted oncoplastic breast surgery in breast-conserving therapy of early breast cancer.


Breast Care ◽  
2020 ◽  
pp. 1-9
Author(s):  
Ida Oberhauser ◽  
Jasmin Zeindler ◽  
Mathilde Ritter ◽  
Jeremy Levy ◽  
Giacomo Montagna ◽  
...  

<b><i>Background:</i></b> The aim of this study was to compare the risk of complications and recurrence between oncoplastic and conventional breast surgery. <b><i>Methods:</i></b> This is a retrospective analysis of a consecutive series of 436 patients with stage I–III breast cancer who underwent surgery at the University Hospital of Basel between 2011 and 2018. <b><i>Results:</i></b> The nipple/skin-sparing mastectomy (NSM/SSM) group showed significantly more delayed wound healing (32.7 vs. 5.8%, <i>p</i> &#x3c; 0.001) and skin necrosis (13.9 vs. 1.9%, <i>p</i> = 0.020) compared to conventional mastectomy (CM), which corresponded to significantly higher odds of short-term complications (OR 2.34, 95% CI 1.02–5.35, <i>p</i> = 0.044). The incidence rate of long-term morbidity in oncoplastic breast-conserving surgery (OBCS) was significantly higher compared to conventional breast-conserving surgery (CBCS; 25.5 vs. 11.3 per 100 patient years [PY], <i>p</i> &#x3c; 0.001), in particular concerning chronic pain (13.3 vs. 6.6, <i>p</i> = 0.011) and lymphedema (4.1 vs. 0.4, <i>p</i> = 0.003). Seroma as a long-term morbidity occurred more often in the CM group compared to the NSM/SSM group (5.8 vs. 0.5 per 100 PY, <i>p</i> = 0.004). Patients received adjuvant treatment earlier after CM compared to NSM/SSM (HR 1.83, 95% CI 1.05–3.19, <i>p</i> = 0.034). There were no significant differences in the incidence of positive margins nor in the odds of recurrence after OBCS versus CBCS and after NSM/SSM versus CM. <b><i>Conclusions:</i></b> Even though the present study confirmed expected differences in complications and morbidity, it suggested that oncoplastic surgery is oncologically safe. Patients undergoing NSM/SSM should be followed closely to allow early detection and treatment of frequently associated complications and ensure timely start of adjuvant therapy.


2021 ◽  
Vol 94 ◽  
pp. 102158
Author(s):  
Alexander Bartram ◽  
Fiona Gilbert ◽  
Alastair Thompson ◽  
G Bruce Mann ◽  
Amit Agrawal

2021 ◽  
pp. 1-10
Author(s):  
Katrine Rye Hauerslev ◽  
Jens Overgaard ◽  
Tine Engberg Damsgaard ◽  
Helle Mikel Hvid ◽  
Eva Balling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document